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Background: Hmg-CoA reductase inhibitors (statins) are widely used to prevent disease associated with vascular
disease and hyperlipidemia. Although side effects are uncommon, clinical observations suggest statin exposure may
exacerbate neuromuscular diseases, including peripheral neuropathy and amyotrophic lateral sclerosis. Although
some have postulated class-effects, prior studies of hepatocytes and myocytes indicate that the statins may exhibit
differential effects. Studies of neuronal cells have been limited.
Methods: We examined the effects of statins on cultured neurons and Schwann cells. Cultured spinal motor
neurons were grown on transwell inserts and assessed for viability using immunochemical staining for SMI-32.
Cultured cortical neurons and Schwann cells were assessed using dynamic viability markers.
Results: 7 days of exposure to fluvastatin depleted spinal motor neurons in a dose-dependent manner with a KD
of< 2 μM. Profound neurite loss was observed after 4 days exposure in culture. Other statins were found to
produce toxic effects at much higher concentrations. In contrast, no such toxicity was observed for cultured
Schwann cells or cortical neurons.
Conclusions: It is known from pharmacokinetic studies that daily treatment of young adults with fluvastatin can
produce serum levels in the single micromolar range. We conclude that specific mechanisms may explain
neuromuscular disease worsening with statins and further study is needed.
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Hmg-CoA reductase inhibitors (statins) are widely used
for lowering cholesterol and the prevention of cardiovas-
cular and cerebrovascular morbidity and mortality. In-
deed, the use of statins has become more prevalent over
time and selected populations, such as those discharged
after hospital admission for stroke, have prevalence rates
for statin prescription exceeding 80% [1].
Side effects of statin treatment are relatively uncom-
mon. Rhabdomyolysis predominates as a side effect that
may necessitate treatment cessation [2,3]. Myalgias are
more prevalent but often accepted as part of treatment
[4]. Laboratory studies to investigate the mechanisms
underlying muscle-related effects have shown that sta-
tins have negative effects on oxidative phosphorylation
by muscle mitochondria [5]. The concentrations at which* Correspondence: bmurins1@jhmi.edu
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reproduction in any medium, provided the orspecific statins produce these effects varies widely and are
generally considered to be outside the normal pharmaco-
logical dosing range except for cerivistatin (now with-
drawn from the market) and possibly fluvastatin [6]. More
recent studies have shown that statins alter important sec-
ond messenger events, e.g., the linkage of proteins to
membrane via lipophilic isoprenyl molecules [5] the syn-
thesis of which is directly inhibited by statins [7].
Clinical observations have suggested that statin expos-
ure may unmask or accelerate the course of amyotrophic
lateral sclerosis, (ALS) [8]. Substantial controversy has
accompanied these observations and based on current
studies, it is not clear whether there is a causal associ-
ation or merely selection bias [9,10]. Selection bias could
arise if concerns about statins among ALS patients and
their physicians lead to increased reporting of suspected
effects. At present several questions remain unanswered.
Among these is whether there is evidence that statins
are directly toxic to spinal motor neurons. An additionalral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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regards to peripheral neuropathy. Large scale epidemio-
logical studies have suggested that statins are associated
with an increased risk for peripheral neuropathy [11,12]
but the magnitude and significance of this risk remains
unresolved.
The culture of spinal motoneurons in organotypic
spinal cord cultures has been an instructive methodology
to better understand the neurobiology of the primary
motor neurons [13] and has been used as a screening
tool for the examination of potential candidate drugs for
neuroprotective strategies in ALS [14]. Because of per-
sistent concerns that statins may impact the course of
ALS and prompt the development of peripheral neur-
opathy, we sought to examine the effects of statins on
spinal motoneurons in culture.
Methods
Spinal motoneuron cultures
All reagents were obtained from Sigma-Aldrich un-
less otherwise specified. Organotypic spinal cord cul-
tures were prepared under sterile conditions from
the lumbar spinal cords of 8-day old rat pups, using
an approved protocol as previously described [13]. In
brief, transverse 350 mm sections were prepared with a
McIlwain tissue chopper. Sections were suspended in ster-
ile Gey's balanced salt solution (GIBCO) with glucose
(6.4 mg/ml) and separated with gentle perturbation. Slices
were transferred to Millipore trans-well inserts (30 mm
Millicell-CM, 0.4 mm pore membranes, Millipore,
Bedford, MA). The transwell inserts were placed in 35 mm
culture wells (Nalgene) containing 1 ml of growth medium
and cultured at 37° C in a humidified 5%CO2/95% air incu-
bator (Forma Scientific, Marietta OH). Growth medium
consisted of Minimal essential medium-25 mM HEPES
(50% vol), heat-inactivated horse serum (25% vol), and
Hanks' balanced salt solution (Life Technologies, Rockville)
(25% vol), supplemented with D-glucose (25.6 mg/ml) and
glutamine (2 mM), final pH 7.2. Cultures were fed twice
weekly for 14 days prior to treatment. Treatments
were carried out for 7 days with a change of medium
after 4 days . Statins (simvastatin (lactone) and fluvas-
tatin from LKT Laboratories, St. Paul MN) were sus-
pended in DMSO and diluted in growth medium before
addition to culture. Control cultures contained DMSO at
appropriate concentrations, in all cases less than 0.1%.
Cortical neuron cultures
Cortical neuron cultures were prepared as previously
described from E18 rats [15]. Cultures were plated on
poly-D-lysine coated plates at a density of 106 cells/ml,
and established for 2 weeks prior to experimental assess-
ment. Plating medium consisted of minimal essential
medium containing 10% fetal bovine serum and antibiotics(1% of penicillin G 104 U/ml, streptomycin 10 mg/ml,
amphotericin B 25 ug/ml). Three hours after plating,
medium was changed to culture medium consisting
of Neurobasal medium with 1x B-27 supplement (Life
Technologies, Rockville, MD).
Schwann cell cultures
Schwann cell cultures were prepared as previously
described from 1-day-old rat pups[16,17]. Cultures were
established for 2 weeks prior to experimental assess-
ment. Culture medium consisted of Neurobasal medium
(GIBCO) with 1% fetal bovine serum (Hyclone, Logan
UT) and glial cell line-derived neurotrophic factor
(GDNF,) at 10 ug/ml. Schwann cells were plated into
96-well plates, using brief trypsinization, 24 h prior
to experimental treatment.
Immunochemistry and assessment of spinal motoneuron
cultures
Cultures were fixed with 4% paraformaldehyde in 0.1 M
Sorenson's buffered solution (pH 7.4) for 30 min at room
temperature. Immunochemistry was performed as previ-
ously described [18]. Slices were permeabilized with
methanol, 20 min at 4°C. Rinsing with Tris-buffered saline
preceded blocking with 10% normal goat serum, 1 h at
room temperature. Exposure to primary antibody (SMI-
32, 1:8000) was at 4°C overnight. Signal amplification with
Vectastain ABC (Vector, Burlingame, CA) preceded
chromogenic development with diamino-benzidine (DAB)
(Polyscience, Warrington, PA).
Spinal motor neurons were specifically identified in the
organotypic slices based on cell size, morphology, location
in the ventral horn, and dense staining with SMI-32.
Motor neuron counts were carried out in a blinded fash-
ion on 12–16 explants for each condition and confirmed
by a second investigator.
Additional cultures and immunochemical studies were
performed on organotypic slice cultures with 4 days of
treatment to ascertain whether neuritic degeneration
preceded motoneuron degeneration. For this, slices were
placed onto collagen-coated transwell inserts, known to
promote the outgrowth of neurites under appropriate
conditions. Chromogenic development was performed
using FITC-conjugated secondary antibody. Visualization
of these slices was carried out using a Nikon Fluorescence
microscope.
Assessment of cortical neuron cultures and Schwann cell
cultures
As a measure of statin cytotoxicity for cortical neurons
and Schwann cells, ATP levels were measured as previ-
ously described [19] with minor modifications. Briefly,
cells were plated into 96 well plates for 24 h prior to
treatment with statins, vehicle control solution or medium
Figure 1 Effect of statin exposure on motoneurons in
organotypic spinal cord slices. Organotypic spinal cord slices were
cultured for 3 weeks with exposure to vehicle control solution (A)
or 20 μM fluvastatin (B) occurring during the last week of culture.
Cultures were stained with SMI32 antibodies developed with DAB as
described in the text, and spinal motoneurons are immediately
apparent in panel A, control cultures. A loss of spinal motoneurons
is evident following treatment with fluvastatin, shown in panel B.
Bar equals 300 μ. C) Quantitative assessment of statin effects on
spinal motoneurons in organotypic slice cultures. Number of spinal
motoneurons per slice for treatment with vehicle control solution or
fluvastatin at 2 μM, 20 μM and 200 μM, pravastatin 200 μM and
simvastatin 200 μM. All treatment groups demonstrated statistically
significant decreases from control, after correction for multiple
comparisons.
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ment, measurement of ATP levels was performed using a
commercially available luciferase-linked ATPase enzym-
atic assay (Vialight Plus, Cambrex).
Statistical analysis
The number of spinal motor neurons in the slices of the
experimental groups did not follow a normal distribu-
tion, for this reason median values are reported. For be-
tween group comparisons, data were transformed using
a logarithmic function (log (N+ 1)). Comparisons be-
tween groups were made on transformed data using a
Chi-squared test with correction for multiple compari-
sons. 50% toxicity value for fluvastatin was estimated
from data following a log-linear transformation of the
data.
Results
Three commonly used statins were tested for toxicity to
spinal motoneurons in culture, these included fluvastatin,
pravastatin, and simvastatin. As a group, the organotypic
slice cultures retained normal conformational properties
and were adherent to the membrane indicative of overall
cellular integrity, consistent with observations of little or
no toxicity of statins for glial cells. Spinal motor neurons
were strikingly depleted or absent from cultures exposed
to fluvastatin, compare Figure 1A and 1B.
Quantitation of spinal motoneurons showed that the
median number per slice was 15 in the vehicle control
group. The median number of motoneurons per slice
was 0 in the 200 μM fluvastatin and simvastatin treat-
ment groups, a significant decrease in motoneuron num-
bers (p< .001), Figure 1C. Treatment with 200 μM
pravastatin yielded a median of 1 cell per slice, and also
showed toxicity compared with control (p< .001). A lim-
ited dose–response curve for fluvastatin was obtained.
Fluvastatin at 20 μM, was toxic for cultured motoneur-
ons, median cells per slice was 0, (p< .001). Fluvastatin
at 2 μM, was associated with partial toxicity, the median
number of motoneurons of 5. This was significantly dif-
ferent from control, (p< .001) and from 20 μM and
200 μM fluvastatin, (p< .001). Replicate experiments
showed analogous results.
Further assessment was made using cultures with only
4 days of statin exposure. Control organotypic slice cul-
tures grown on collagen coated membranes exhibited
robust ventral neurite outgrowth after 2.5 weeks in cul-
ture. By contrast, organotypic slices exposed to 200 μM
fluvastatin for 96 h demonstrated profound neuritic de-
generation, Figure 2. Motoneuron staining, somewhat
reduced, was still observable in these cultures.
In order to assess whether spinal motor neurons were
unusual in exhibiting cytotoxic responses to statin ex-
posure, we assessed the effects of statin treatment oncortical neuron cultures and primary cultures of Schwann
cells. No potentially relevant cytotoxic effects were
observed for these cell types, Figure 3.
Discussion
In this study, we demonstrate that in vitro exposure of
spinal motoneurons to selected statins, especially fluvasta-
tin, resulted in marked cell loss. Shorter term exposures to
fluvastatin resulted in neuritic degeneration. Other statins,
specifically pravastatin and simvastatin, also exhibited
toxic effects towards spinal motor neurons, but at much
higher concentrations. The susceptibility of spinal motor
neurons was in contrast to primary cultures of cortical
neurons and peripheral nerve-derived Schwann cells
which did not demonstrate significant deleterious changes.
The results of this study provide evidence that specific
Figure 2 Effect of statin exposure on neurite outgrowth. Fluvastatin exposure for 96 h resulted in a marked degeneration of neurites
growing out from organotypic spinal cord cultures, when plated on collagen coated membranes. Cultures were stained with SMI32 antibodies
developed with FITC-conjugated secondary antibody as described in the text. Vigorous outgrowth of ventral horn neurites is apparent in panel A,
montage view (bar equals 1 mm) and panel B, detail view (bar equals 500 μm). Neuritic degeneration is seen in panel C (bar equals 500 μm).
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neuromuscular disease exacerbation with statin exposure,
however the clinical implications of this study remain to
be determined.
There are multiple factors which might account for the
differences between the clear in vitro toxicity reported
here and the uncertainty surrounding observations of sta-
tin toxicity for spinal motor systems in clinical settings.
Among the biological factors proposed to explain the wide
clinical tolerability of statins are pharmacokinetics. Statins
as a group are subject to high first-pass metabolism by the
liver. This means that systemic levels are substantially
below what might be predicted based on simple dilutional
calculations. Statins do vary in the degree of first pass
metabolism with the earlier-developed statins being more
extensively metabolized [6]. Interestingly the low first-pass
metabolism of cerivistatin, initially hailed as a break-
through, may have contributed to the high-rate of ser-
ious adverse events [3]. In addition, most statins are
hydrophobic, with several newer statins being especially
so. Pravastatin is uniquely hydrophilic and likely requiresFigure 3 Effect of statin exposure on primary Schwann cell and
cortical neuron cultures. A) Statin treatment of Schwann cells for
24 h did not result in significant toxicity except for very high
concentrations of fluvastatin and simvastatin (500 μM). Three
different statins are shown: fluvastatin, solid line; simvastatin, long
dash; pravastatin, short dash. B) Statin treatment of cortical neurons
for 24 h did not result in significant toxicity. Three different statins
are shown: fluvastatin, solid line; lovastatin, long dash; pravastatin,
short dash. Data are shown normalized to vehicle control, error bars
indicate standard deviation from the mean.distinct consideration when considering systemic effects.
In our study, there was the suggestion that pravastatin
may be somewhat less toxic to cultured spinal motoneur-
ons that fluvastatin, however further studies are needed.
Finally, compartmental pharmacokinetics may limit the
effects of statins on spinal motor neurons. The extent to
which specific statins attain significant concentrations in
the spinal fluid is not well understood. Studies in labora-
tory animals have indicated that the permeability of lipo-
philic statins, simvastatin and lovastatin into rat brain is
orders of magnitude greater than that of pravastatin [20].
Thus, there are multiple pharmacokinetic reasons why
statins may exhibit lower in vivo than in vitro toxicity.
Pharmacokinetic data for fluvastatin from clinical trials
of the drug, suggest that a more cautious interpretation
may warranted. From the early pharmacokinetic studies in
man, it is estimated that the peak daily serum levels of flu-
vastatin after a 40 mg dose is in the low single micromolar
range [21]. The results of the fluvastatin dose response
studies we report here provide evidence that the drug con-
centration necessary to produce 50% toxicity for spinal
motoneurons in culture is less than 1 μM. Taken together,
these data suggest that systemic levels of statins may ap-
proach levels that are toxic to spinal motoneurons and
that particular mechanisms must account for the relatively
infrequent occurrence of clinically demonstrable toxicity.
Perhaps sequestration of spinal motoneurons in the spinal
space is one such mechanism.
The pharmacokinetics of fluvastatinare are such that
peak concentrations are present in the body for only a
short period of time following single-dose administration
[21]. For this reason, early fluvastatin treatment followed a
twice-daily dosing regimen. This approach has subse-
quently been supplanted by the use of extended release
formulations but for reasons that are not known, fluvasta-
tin remains among the least commonly prescribed statins.
Based on these studies, it is not possible to specify
a mechanism or mechanisms by which statins pro-
duce depletion of spinal motoneurons in culture. In-
triguingly, somewhat analogous effects of statins have
been reported in myotube cultures, where it was
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clearly evident toxicity, the effects of pravastatin were
apparently more mild [6]. Mechanisms by which sta-
tins have produced undesirable and desirable effects
in other systems continue be explored. The effects of
statins are widely acknowledged to be protean. Statins
have profound impacts on inflammatory signaling
pathways [22,23], are known to effect the linkage of
G proteins to the various cell membranes [24,25], are
thought to play a role in cancer signaling [26], have
been shown to have direct actions on carnitine palmi-
toyl transferase localized to mitochondrial membranes
[6], can disrupt oxidative phosphorylation and mito-
chondrial membrane potential [6] as well as interfer-
ing with cholesterol synthesis [27]. As an example of
a one potential mechanism, statins have been shown
to disrupt the attachment of Rho and Ras-family G
proteins to cell membranes. It is interesting that one
Ras-family protein, Rab5, is critically important for early
neuronal endocytosis [28] and has been implicated in pro-
ducing an ALS phenotype resulting from Alsin mutations
[29]. The se animals may represent an especially attractive
model system for further exploration of statin effects on
motor neurons. Among these studies is a report that sta-
tins promote apoptosis of a glioma cell line mediated by
ERK1/2 and AKT [25]. This is in contrast to our observa-
tions of robust resistance to statin effects in primary
cultures of Schwann cells suggesting that important differ-
ences between normal and transformed glia that underlie
statin effects on glioma cells. Thus, statins have a variety
of effects on cell signaling. We here describe the observa-
tion of deleterious effects on the survival of spinal motor
neurons in culture and because the mechanisms of statin
effects on specific neuronal cell populations remain rela-
tively obscure, additional study is warranted.
Conclusions
In this study, we demonstrate that in vitro exposure of
spinal motoneurons to selected statins, especially fluvasta-
tin, resulted in marked cell loss. Shorter term exposures to
fluvastatin resulted in neuritic degeneration. The results
of this study provide evidence that specific pathophysio-
logical mechanisms may underlie reports of neuromuscu-
lar disease exacerbation with statin exposure.
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